Cytek Biosciences Inc (CTKB)vsMerck & Company Inc (MRK)
CTKB
Cytek Biosciences Inc
$4.61
+1.77%
HEALTHCARE · Cap: $599.22M
MRK
Merck & Company Inc
$144.85
+0.64%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 32104% more annual revenue ($66.57B vs $206.71M). MRK leads profitability with a 4.8% profit margin vs -39.0%. CTKB earns a higher WallStSmart Score of 41/100 (D).
CTKB
Hold41
out of 100
Grade: D
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+40.6%
Fair Value
$7.34
Current Price
$4.61
$2.73 discount
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$144.85
$62.01 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -25.0% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.19 — expect wider price swings.
CTKB is growing revenue faster at 5.6% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
CTKB scores higher overall (41/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, delivering innovative cell analysis solutions that advance research in immunology, cancer diagnostics, and drug development. The company leverages its proprietary technologies to meet the growing demand for precision in cellular analytics, positioning itself as a key player in the biotechnology sector. With a robust product portfolio and a commitment to exceptional customer support, Cytek is well-equipped to drive transformative discoveries, ultimately enhancing healthcare outcomes and addressing critical challenges in the life sciences.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?